Related Experiment Video
Updated: May 14, 2026

Peptide-based Identification of Functional Motifs and their Binding Partners
Published on: June 30, 2013
Molecular biology for formyl peptide receptors in human diseases
1Department of Pathophysiology, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei 430030, China. yli@zeus.bwh.harvard.edu
Abstract:
Leukocytes accumulate at sites of inflammation and immunological reaction in response to locally existing chemotactic mediators. The first chemotactic factors structurally defined were N-formyl peptides. Subsequently, numerous ligands were identified to activate formyl peptide receptors (FPRs) that belong to the seven-transmembrane G protein-coupled receptor superfamily. FPRs interact with this menagerie of structurally diverse pro- and anti-inflammatory ligands to possess important regulatory effects in multiple diseases, including inflammation, amyloidosis, Alzheimer's disease, prion disease, acquired immunodeficiency syndrome, obesity, diabetes, and cancer. How these receptors recognize diverse ligands and how they contribute to disease pathogenesis and host defense are basic questions currently under investigation that would open up new avenues for the future management of inflammation-related diseases.
Related Concept Videos
Signal Sequences and Sorting Receptors
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Pharmacogenomics: Identification of New Drug Targets
Transducer Mechanism: G Protein–Coupled Receptors
GPCRs are also called heptahelical, 7TM, or...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...

